Market Cap : 8.39 B | Enterprise Value : 7.55 B | PE Ratio : At Loss | PB Ratio : 18.35 |
---|
NAS:NVCR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:NVCR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
NovoCure's Capital Expenditure for the three months ended in Mar. 2022 was $-5.09 Mil. Its Revenue for the three months ended in Mar. 2022 was $137.55 Mil.
Hence, NovoCure's Capex-to-Revenue for the three months ended in Mar. 2022 was 0.04.
The historical data trend for NovoCure's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, NovoCure's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where NovoCure's Capex-to-Revenue falls into.
NovoCure's Capex-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-24.17) | / | 535.031 | |
= | 0.05 |
NovoCure's Capex-to-Revenue for the quarter that ended in Mar. 2022 is calculated as
Capex-to-Revenue | = | - Capital Expenditure | / | Revenue |
= | - (-5.093) | / | 137.547 | |
= | 0.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Thank you for viewing the detailed overview of NovoCure's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Weinberg Uri | officer: Chief Science Officer | NOVOCURE INC., 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
Groenhuysen Wilhelmus Cm | officer: Chief Operating Officer | C/O NAVTEQ CORPORATION 222 MERCHANDISE MART STE 900 CHICAGO IL 60654 |
Danziger Asaf | director, officer: Chief Executive Officer | 5 NACHUM CHAT ST. TIRAT HACARMEL L3 5112302 |
Leung Gabriel | director | C/O PERNIX THERAPEUTICS HOLDINGS, INC. 10 NORTH PARK PLACE, SUITE 201 MORRISTOWN NJ 07960 |
Shah Pritesh | officer: Chief Commercial Officer | C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Leonard Frank X | officer: Chief Development Officer | 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Cordova Ashley | officer: Chief Financial Officer | 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 |
Madden Martin J. | director | C/O MICROBOT MEDICAL INC. 175 DERBY STREET 27/1 HINGHAM MA 02043 |
Benaim Ely | officer: Chief Medical Officer | C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE MD 20850 |
Doyle William F | director, officer: Executive Chairman | PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DOYLE WILLIAM F a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;} |
Ambrogi Michael J. | officer: Chief Operating Officer | 195 COMMERCE WAY PORTSMOUTH NH 03801 |
Longsworth Todd Christopher | officer: General Counsel | NOVOCURE, 20 VALLEY STREAM PARKWAY SUITE 300 MALVERN PA 19355 |
Hilleman Jeryl L | director | C/O INTERSECT ENT, INC. 1555 ADAMS DRIVE MENLO PARK CA 94025 |
Mccoy Sherilyn S | director | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Hung David | director | C/O AXOVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018 |
From GuruFocus
Other Sources
By Fool 2022-01-29
By Zacks 2021-07-29
By Zacks 2021-10-28
By Seekingalpha 2021-10-28
By Fool 2022-01-20
By Seekingalpha 2022-02-28
By Zacks 2021-10-12
By Zacks 2021-07-22
By Seekingalpha 2021-11-30
By Zacks 2022-02-16
By Seekingalpha 2022-01-01